...
首页> 外文期刊>Neurourology and urodynamics. >A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints
【24h】

A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints

机译:一种新型无铅,微型植入胫骨神经神经性神经性调节系统,用于管理过度活跃的膀胱抱怨

获取原文
获取原文并翻译 | 示例
           

摘要

Background Overactive bladder is a chronic condition affecting lower urinary tract function that has a significant negative impact on QoL. Objective Evaluation of the BlueWind implantable tibial nerve system performance and safety in refractory OAB. Design, Setting, and Participants Intervention A 6‐month multi‐center prospective intervention study. Outcome Measurements and Statistical Analysis Objective assessment was done by voiding diary parameters including voids/day, volume voided/day, urgency assessment, leaking episodes/day, pads used/day, leak severity, and clinical success defined as a ≥50% reduction in the number of leaks/day or number of voids/day or number of episodes with degree of urgency 2 or a return to 8 voids/day on a 3 Day diary. Subjective assessment was based on OAB‐q including HRQL and symptom severity score. Safety was evaluated by adverse event (AE) analysis. Results and Limitations Thirty‐four of the 36 implanted subjects completed the study. One subject withdrew voluntarily and one developed inflammation necessitating removal of the system. In the remaining subjects, 71% experienced clinical success at 6 months. Leaks/day, leak severity, and pad changes/day decreased significantly over time with 27.6% of urge incontinence subjects that became “dry.” Voids/day, degree of urgency, volume/void, pads changed improved significantly. All quality of life aspects (concern, coping, sleep, and social) improved as well as symptom severity scores measured by the OAB‐q. Adverse events included: implant site pain (13.9%), suspected infection (22.2%), and procedural wound complications (8.3%). Conclusions The BlueWind implantable tibial nerve stimulator is a safe, minimally invasive system that affords OAB patients significant improvements. Patient Summary The performance and safety of the BlueWind RENOVA? implantable tibial nerve neuromodulator for OAB was tested. Our preliminary results demonstrate that the system has a low risk safety profile and may be considered an effective treatment option for OAB management.
机译:背景技术过度活跃的膀胱是影响低尿路函数的慢性病,​​对QOL具有显着的负面影响。难治性OAB的蓝风植入胫骨神经系统性能和安全性的客观评价。设计,设定和参与者干预一个6个月的多中心前瞻性干预研究。结果测量和统计分析客观评估是通过空隙日记参数来完成,包括空隙/天,体积空隙/日,尿液发作/日,使用的泄漏发作/日,泄漏严重程度和临床成功被定义为≥50%泄漏/日或空隙数或空隙数量或急性程度的剧集数量,或者返回到3天日记中的返回到& 8个空隙/天。主观评估基于OAB-Q,包括HRQL和症状严重性得分。通过不良事件(AE)分析评估安全性。结果和限制36个植入受试者中的36个三十四所完成的研究。一个受试者自愿退出,一个突发炎症需要去除系统。在其余的受试者中,71%的临床成功在6个月内成功。泄漏/日,泄漏严重程度和垫变化/日随着时间的推移而显着降低,急需失禁受试者变得“干燥”。空隙/日,紧急程度,体积/空隙,垫改变显着改变。所有生活方式(关注,应对,睡眠和社会)的所有质量都改善了以及由OAB-Q测量的症状严重性分数。包括不良事件:植入部位疼痛(13.9%),可疑感染(22.2%)和程序伤口并发症(8.3%)。结论Bluewind植入胫骨神经刺激器是一种安全,微创的系统,可提供oab患者的显着改善。患者摘要蓝风道·雷诺瓦的性能和安全?测试OAB的可植入胫骨神经神经调节剂。我们的初步结果表明,该系统具有低风险安全性,可被认为是OAB管理的有效治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号